CMPS — COMPASS Pathways Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Nvidia, Crinetics Pharmaceuticals, Rivian Automotive
U.S. STOCKS ON THE MOVE-Tesla, Nvidia, Rivian
Compass rises on positive late-stage trial data for depression drug
Brief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications
Brief: Compass Pathways Says FDA Granted NDA Rolling Review Request & Awarded Commissioner's National Priority Voucher
U.S. STOCKS ON THE MOVE-Zoom, Compass Pathways, X-Energy
Compass Pathways rises after FDA fast-tracks psychedelic drug research
US FDA moves to fast-track psychedelic drugs after Trump order (updated)
Explainer: What to know about psychedelic therapies cited by Trump
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
Psychedelic drug developers rise after Trump signals regulatory support
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Psychedelic drug developers rally as Trump orders FDA to expedite reviews (updated)
Psychedelic drug makers rally as Trump orders FDA to expedite reviews